RESULTS // ENDPOINTS // RECORD
PT-141 Results in the Studies
Endpoints, extension data, and the results that did not go the expected way.
The short version
PT-141 results read like a clean trial record with honest edges. The main results: in the approved group, desire went up and distress went down versus placebo — both statistically significant, both small [3]. Long-term, the gains held and no new safety problem appeared, but nausea kept showing up [4].
The results that do not flatter the drug get logged too. One animal study found PT-141 did not boost sexual reward in a hamster model [6]. Independent re-analyses say the human effect, though real, is modest [3]. One old erectile-dysfunction study now carries an Expression of Concern and is treated as disputed [7]. Below, each result is tied to its study. No result here is a dosing instruction.
Trial endpoints
The RECONNECT Phase 3 results (n=1267 premenopausal women with HSDD): bremelanotide 1.75 mg as-needed met both coprimary endpoints over 24 weeks — FSFI-desire +0.35 (P<.001) and FSDS-DAO item 13 -0.33 (P<.001) versus placebo [3]. The trials enrolled premenopausal women only; that defines who the results apply to [3].
Long-term and mechanistic results
The 52-week open-label extension (684 women) produced sustained desire improvement and no new safety signals; nausea (40.4%), flushing (20.6%), and headache (12.0%) were the most common drug-related events [4]. The 2022 fMRI study (31 women) showed MC4R agonism raised desire for up to 24 hours and altered brain processing of erotic stimuli [5]. A 2026 systematic review and meta-analysis pooled the trials: improved total FSFI plus desire and arousal subscales [15].
PT-141 reviews
Across published reviews the result is consistent: bremelanotide is a centrally acting agent with good evidence for HSDD, set against few approved alternatives [8][13]. Reviews frame it among emerging FSD therapies where Phase 3 endpoint challenges have impeded approvals [9], place it within multidisciplinary treatment algorithms for premenopausal HSDD [10], and note it within unresolved diagnostic and ethical debates about HSDD [12]. Trial-design limitations are flagged across the comparator class [11]. These are literature reviews, not user testimonials.
Negative and disputed results
The record's honest edges. In female Syrian hamsters, neither low- nor high-dose bremelanotide changed melanocortin-receptor mRNA in the mesolimbic dopamine system, and it did not enhance sexual reward (conditioned place preference) — suggesting no action on the VTA-NAc reward circuit [6]. Independent re-analyses argue the human desire/distress effects are small and of debatable clinical meaning [3]. A 2008 erectile-dysfunction salvage study carries a 2023 Expression of Concern and should be treated as disputed [7]. Logged, not buried.